



Confederation of Indian Industry



Department of Pharmaceuticals
Ministry of Chemicals and Fertilizers
Government of India

14th National Pharmaceutical Conclave 2017

"Maximizing the Pharmaceutical Opportunity for India: Vision and Roadmap- 2025"
20 – 21 December 2017: Hotel Le Meridien, New Delhi

PROGRAM GRID

| Day 1: 20 December- Wednesday | | Page |
|--------------------------------------|--|-------------|
| 0830-1000 Hrs | Registration | |
| 1000-1100 Hrs | Inaugural Session | 1 |
| 1100-1115 Hrs | Networking Tea | |
| 1115-1215 Hrs | Panel Discussion I: Building a robust roadmap to drive excellence in quality in pharmaceuticals | 2 |
| 1215-1315 Hrs | Panel discussion II: Driving India's Export/ Import competitiveness | 3 |
| 1315-1415 Hrs | Networking Lunch | |
| 1415-1515 Hrs | Panel Discussion III: Indian API Pharmaceutical Industry - Risks, Challenges and Way Forward | 4 |
| 1515-1530 Hrs | Networking Tea | |
| 1530-1645 Hrs | Panel discussion IV: Ease of doing business in Pharma | 5 |
| 1645-1745 Hrs | Panel Discussion V: Fourth generation technologies in pharmaceuticals- Revolutionizing Healthcare | 7 |
| Day 2: 21 December- Thursday | | |
| 0930-1030 Hrs | Registration | |
| 1030-1130 Hrs | Panel discussion VI: Robust pharmaceutical policy to meet India's pharma goals | 8 |
| 1130-1145 Hrs | Networking Tea | |
| 1145-1245 Hrs | Panel Discussion VII: Interactions between academia and pharmaceutical industry- Some experiences and scaling up | 9 |
| 1245-1330 Hrs | Valedictory Session | 10 |
| 1330 Hrs | Conclave Ends with Networking Lunch | |





Confederation of Indian Industry



Department of Pharmaceuticals
Ministry of Chemicals and Fertilizers
Government of India

14th National Pharmaceutical Conclave 2017

"Maximizing the Pharmaceutical Opportunity for India: Vision and Roadmap- 2025"

20 – 21 December 2017: Hotel Le Meridien, New Delhi

PANEL DISCUSSION I

20 December 2017; 1115 – 1215 HRS

Panel discussion: Building a robust roadmap to drive excellence in quality in pharmaceuticals

India is amongst the most favourable destination for the manufacturing of pharmaceuticals. Indian pharmaceutical sector accounts for about 2.4 per cent of the global pharmaceutical industry in value terms, 10 per cent in volume terms, and 20 per cent of global exports in generics. It is expected to expand at a Compound Annual Growth Rate (CAGR) of 22.42 per cent over 2015-20 to reach USD55 billion. To stay relevant and develop a competitive advantage, we need to continuously focus on developing capabilities in terms of quality to define 'Quality system' Vision for India in order to consolidate our position in Pharmaceutical sector over next 15-20 years. This session aims to identify key areas of interventions in terms of quality so as to highlight the value proposition of Indian pharmaceutical globally.

| | | |
|---------------|----------------------------------|---|
| 1115-1120 Hrs | Opening Remarks by the Moderator | Mr Manish Kumar Director PricewaterhouseCoopers (PwC) |
| 1120-1135 Hrs | Special Address | Dr GN Singh Drugs Controller General of India Central Drugs Standard Control Organization |
| 1135-1205 Hrs | Remarks by the Panelists | Dr Rajiv I Modi Chairman, CII National Committee on Pharma Chairman & Managing Director, Cadila Mr Srinivivasan Managing Director Pfizer Healthcare India Ltd. Dr Ganadhish Kamat Executive Vice President global quality head Dr. Reddy's Laboratories Dr Ranjana Pathak Global Head – Quality Cipla Ltd. |
| 1205-1215 Hrs | Closing Remarks by the Moderator | |





Confederation of Indian Industry



Department of Pharmaceuticals
Ministry of Chemicals and Fertilizers
Government of India

14th National Pharmaceutical Conclave 2017

"Maximizing the Pharmaceutical Opportunity for India: Vision and Roadmap- 2025"

20 – 21 December 2017: Hotel Le Meridien, New Delhi

PANEL DISCUSSION II

20 December 2017; 1215 – 1315 HRS

Panel discussion: Driving India's Export/ Import competitiveness

The Indian pharmaceutical industry is the largest supplier of cost effective generic medicines to the developed world. With the widest range of medicines available for exports and with the availability of the largest number of approved pharmaceutical manufacturing facilities, India is all set to become the leader of pharmaceutical exports to the world. This session will focus on particularly the large ones have set up their subsidiary companies, regional offices or taken over local companies in other geographies and many have even set up their manufacturing plants in developed nations too.

| | | |
|---------------|----------------------------------|---|
| 1215-1220 Hrs | Opening Remarks by the Moderator | Mr Gagan Singh CMD Astra Zeneca |
| 1220-1230 Hrs | Special Address | Ms Rita A Teotia* Secretary Department of Commerce |
| 1230-1305 Hrs | Remarks by the Panelists | Shri Madan Mohan Reddy Chairman, Pharmexcil MD, Aurobindo Pharma Ltd Mr. G Sathiya Galderma India Pvt. Ltd. Mr VC Nannapaneni* Chairman and Managing Director Natco Mr RC Juneja* Managing Director Mankind |
| 1305-1315 Hrs | Closing Remarks by the Moderator | |
| 1315-1415 Hrs | Networking Lunch | |





Confederation of Indian Industry



Department of Pharmaceuticals
Ministry of Chemicals and Fertilizers
Government of India

14th National Pharmaceutical Conclave 2017

"Maximizing the Pharmaceutical Opportunity for India: Vision and Roadmap- 2025"

20 – 21 December 2017: Hotel Le Meridien, New Delhi

PANEL DISCUSSION III

20 December 2017; 1415 – 1515 HRS

Panel discussion: Indian API Pharmaceutical Industry - Risks, Challenges and Way Forward

India's absolute dependence over APIs on China along with some European nations has been quite alarming. Indian API industry is plagued with issues revolving around increased dependence on Chinese API imports and a few non-compliance incidents. India is importing API's and intermediates worth 3 billion dollars from China, which is dictating the market in terms of availability and pricing today. This calls for an urgent need for India to have a re-look at its API strategy. The Indian industry is anticipating quick measures and robust steps where government steps-in as a key enabler for manufacturing top priority molecules which are in demand to prevent any emergency which may occur owing to over dependency.

| | | |
|---------------|----------------------------------|---|
| 1415-1420 Hrs | Opening Remarks by the Moderator | Mr Ravind Mithe BPS leader KPMG, India |
| 1420-1450 Hrs | Special Address | Dr R K Vats* Additional Secretary Ministry of Health & Family Welfare |
| 1440-1510 Hrs | Remarks by the Panelists | Dr V M Katoch NASI-ICMR Chair on Public Health Research Rajasthan University of Health Sciences, Jaipur Mr Gaurav Mathur Managing Director Teva India Shri Dinesh Dua Vice Chairman Pharmaexcil Senior Representative* Cadila |
| 1510-1515 Hrs | Closing Remarks by the Moderator | |
| 1515-1530 Hrs | Networking Tea | |





Confederation of Indian Industry



Department of Pharmaceuticals
Ministry of Chemicals and Fertilizers
Government of India

14th National Pharmaceutical Conclave 2017

"Maximizing the Pharmaceutical Opportunity for India: Vision and Roadmap- 2025"

20 – 21 December 2017: Hotel Le Meridien, New Delhi

PANEL DISCUSSION IV

20 December 2017; 1530 – 1645 HRS

Panel discussion: Ease of doing business in Pharmaceuticals

India is looking to make pharma more conducive for growth and to boost investment in the sector. Ease of Doing Business is highly desired by the industry, as the amount of effort and time spent to get multiple clearances sometimes becomes overwhelming. This session aims to bring forth various difficulties faced by the pharma industry, especially in respect of initiating business in India and improving the regulatory mechanism for the pharmaceutical sector. The sessions would also focus on action plans for states to sharpen focus on improving ease of doing business in pharmaceuticals.

| | | |
|---------------|----------------------------------|---|
| 1530-1535 Hrs | Opening Remarks by the Moderator | Mr Rakesh Bamzai CoChairman, CII National Committee on Pharmaceuticals, & President, Mylan |
| 1535-1620 Hrs | Special Address | Shri Rajneesh Tingal* Joint Secretary Department of Pharmaceuticals Shri Alok Kumar* Advisor Niti Aayog Dr S Eswara Reddy Joint Drugs Controller General of India Central Drugs Standard Control Organization <i>Release of EoDB Report in the Session</i> |
| 1620-1640 Hrs | Remarks by the Panelists | Mr Vivek Vasudev Kamath Managing Director MSD Pharmaceuticals Ltd. Mr Amit Kumar Group president and Country head- Corporate Banking- Yes Bank |
| 1640-1645 Hrs | Closing Remarks by the Moderator | |





Confederation of Indian Industry



Department of Pharmaceuticals
Ministry of Chemicals and Fertilizers
Government of India

14th National Pharmaceutical Conclave 2017

"Maximizing the Pharmaceutical Opportunity for India: Vision and Roadmap- 2025"

20 – 21 December 2017: Hotel Le Meridien, New Delhi

PANEL DISCUSSION V

20 December 2017; 1645 – 1745 HRS

Panel discussion: Fourth generation technologies in pharmaceuticals- Revolutionizing Healthcare

The Industry 4.0 has the potential to fundamentally transform pharma operations, opening the door to step-change improvements in performance and products. Several companies have embarked on this journey and are starting to realize the potential of fourth-generation technologies and develop a strategy and road map for the next three to five years to improve efficiencies. Those companies that seize the initiative can give themselves a sustainable competitive advantage in terms of improved supply chain operations, fundamentally improved processes, innovative products, and enhanced productivity. The outcome would be to operate with greater agility, cost-efficiency, and control; and ultimately provide better care for patients. The Sessions would also lay down strategies for adoption and application of these fourth-generation technologies along the R&D pipeline to optimize the discovery and development of novel therapies with better outcomes that are faster, cheaper and more efficient.

| | | |
|---------------|----------------------------------|---|
| 1645-1650 Hrs | Opening Remarks by the Moderator | Senior Representative Microsoft |
| 1650-1700 Hrs | Special Address | Speaker* DST |
| 1700-1725 Hrs | Remarks by the Panelists | Dr. Nimita Limaye CEO Nymro Clinical Consultancy Services Dr. U. Kamachi Mudali Department of Heavy Water Board Mumbai Mr. Vinay Ranade Chief Executive Officer Reliance GeneMedix |
| 1725-1730 Hrs | Closing Remarks by the Moderator | |





Confederation of Indian Industry



Department of Pharmaceuticals
Ministry of Chemicals and Fertilizers
Government of India

14th National Pharmaceutical Conclave 2017

"Maximizing the Pharmaceutical Opportunity for India: Vision and Roadmap- 2025"

20 – 21 December 2017: Hotel Le Meridien, New Delhi

PANEL DISCUSSION VI

21 December 2017; 1030 – 1130 HRS

Panel discussion: Robust pharmaceutical policy to meet India's pharma goals

In the year 2017, Department of Pharmaceuticals came out with Draft Pharmaceutical Policy that witnessed various opinions/ comments from several other departments and industries on various provisions. As India's role becomes progressively significant in the pharmaceuticals, a robust pharmaceutical policy would meet the requirements of changing business environment, boost innovations, advanced manufacturing and R&D with affordable and accessible healthcare. In this Session, key stakeholders would share their expert views on the policy.

| | | |
|---------------|---|--|
| 1030-1040 Hrs | Opening Remarks with Industry perspective | Mr Susheel Umesh Co-Chairman, CII National Committee on Pharmaceuticals & Managing Director & GM, Abbott Healthcare Pvt. Ltd |
| 1040-1125 Hrs | Lead Discussants | Shri Bhupendra Singh Chairman National Pharmaceutical Pricing Authority Shri Sudhansh Pant* Joint Secretary Department of Pharmaceuticals Ministry of Chemicals and Fertilizers Shri Shyamal Misra* Joint Secretary Department of Commerce |
| 1125-1135Hrs | Closing Remarks | Dr Azadar Khan Senior Vice President Sun Pharmaceutical Industries Ltd. |
| 1135-1145 Hrs | Networking Tea | |





Confederation of Indian Industry



Department of Pharmaceuticals
Ministry of Chemicals and Fertilizers
Government of India

14th National Pharmaceutical Conclave 2017

"Maximizing the Pharmaceutical Opportunity for India: Vision and Roadmap- 2025"

20 – 21 December 2017: Hotel Le Meridien, New Delhi

PANEL DISCUSSION VII

21 December 2017; 1145 – 1245 HRS

Interactions between academia and pharmaceutical industry- Some experiences and scaling up

There is little doubt that academic and pharma researchers can accomplish far more together than either can do alone. Several nascent ideas and research works are rattling around already in the minds, labs, and notes of academic researchers – which is one reason why pharma R&D groups should work closely with academic centers. However, many of these collaboration opportunities are being left on the table. This session would aim to explore the mechanisms of pharma-academia R&D collaborations and summarize some key takeaways

| | | |
|---------------|----------------------------------|--|
| 1145-1150 Hrs | Opening Remarks by the Moderator | Prof Raghuram Rao Akkinepally Director NIPER Mohali |
| 1150-1200 Hrs | Special Address | Dr Girish Sahni Director General, CSIR |
| 1200-1235 Hrs | Remarks by the Panelists | Dr Venkata Pale Senior Vice President - Discovery Research - LUPIN LIMITED Mr Ashok Bhattacharya Executive Director Takeda Pharmaceuticals India Pvt. Ltd Dr Neeraj Sharma Head, Technology Development Transfer Department of Science & Technology |
| 1235-1245 Hrs | Closing Remarks by the Moderator | |





Confederation of Indian Industry



Department of Pharmaceuticals
Ministry of Chemicals and Fertilizers
Government of India

14th National Pharmaceutical Conclave 2017

"Maximizing the Pharmaceutical Opportunity for India: Vision and Roadmap- 2025"

20 – 21 December 2017: Hotel Le Meridien, New Delhi

VALEDICTORY SESSION

21 December 2017; 1245 – 1330 HRS

| | | |
|---------------|-----------------|--|
| 1245-1250 Hrs | Key Takeaways | Dr Rajiv I Modi Chairman, CII National Committee on Pharmaceuticals Chairman & Managing Director, Cadila Pharmaceuticals Ltd. |
| 1250-1255 Hrs | Address | Mr Susheel Umesh Co-Chairman, CII National Committee on Pharmaceuticals & Managing Director & GM, Abbott Healthcare Pvt. Ltd |
| 1255-1310 Hrs | Special Address | Mr Amitabh Kant* Chief Executive Officer Niti Aayog |
| 1310-1325 Hrs | Special Address | Ms Anupriya Singh Patel* Honorable Minister of State for Health and Family Welfare |
| 1325-1330 Hrs | Vote of Thanks | Mr Rakesh Bamzai Co-Chairman, CII National Committee on Pharmaceuticals & President, Mylan |





Confederation of Indian Industry



Department of Pharmaceuticals
Ministry of Chemicals and Fertilizers
Government of India

14th National Pharmaceutical Conclave 2017

"Maximizing the Pharmaceutical Opportunity for India: Vision and Roadmap- 2025"

20 – 21 December 2017: Hotel Le Meridien, New Delhi

ASSOCIATION PARTNERS



CONFEDERATION OF
INDIAN PHARMACEUTICAL
INDUSTRY

INSTITUTIONAL PARTNERS



The Indian Society
of International Law (ISIL)

TECHNICAL PARTNERS

